文献类型：期刊文献

英文题名：Nanotechnology platforms for cancer immunotherapy

作者：Yang, Zhaogang[1];Ma, Yifan[2];Zhao, Hai[3];Yuan, Yuan[4];Kim, Betty Y. S.[3]

机构：[1]Univ Texas Southwestern Med Ctr Dallas, Dept Radiat Oncol, Dallas, TX 75390 USA;[2]Ohio State Univ, Dept Chem & Biomol Engn, Columbus, OH 43210 USA;[3]Univ Texas MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA;[4]East China Univ Sci & Technol, Engn Res Ctr Biomat, Minist Educ, Shanghai, Peoples R China

年份：2020

卷号：12

期号：2

外文期刊名：WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY

收录：;EI(收录号：20194607683443);WOS:【SCI-EXPANDED(收录号:WOS:000494741900001)】；

基金：Congressionally Directed Medical Research Programs, Grant/Award Number: BC181476; National Institute of Neurological Disorders and Stroke, Grant/Award Number: R01 NS104315

语种：英文

外文关键词：cancer immunotherapy; immunomodulatory agents; nanoplatforms

摘要：Various cancer therapies have advanced remarkably over the past decade. Unlike the direct therapeutic targeting of tumor cells, cancer immunotherapy is a new strategy that boosts the host's immune system to detect specific cancer cells for efficient elimination. Nanoparticles incorporating immunomodulatory agents can activate immune cells and modulate the tumor microenvironment to enhance antitumor immunity. Such nanoparticle-based cancer immunotherapies have received considerable attention and have been extensively studied in recent years. This review thus focuses on nanoparticle-based platforms (especially naturally derived nanoparticles and synthetic nanoparticles) utilized in recent advances; summarizes delivery systems that incorporate various immune-modulating agents, including peptides and nucleic acids, immune checkpoint inhibitors, and other small immunostimulating agents; and introduces combinational cancer immunotherapy with nanoparticles, especially nanoparticle-based photo-immunotherapy and nanoparticle-based chemo-immunotherapy. Undoubtedly, the recent studies introduced in this review prove that nanoparticle-incorporated cancer immunotherapy is a highly promising treatment modality for patients with cancer. Nonetheless further research is needed to solve safety concerns and improve efficacy of nanoplatform-based cancer immunotherapy for future clinical application. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease